Open AccessA Review of Therapeutic Antibodies in Breast Cancer
Author(s) -
Maryam Eini,
Nahid Zainodini,
Hamed Montazeri,
Parastoo Mirzabeigi,
Parastoo Tarighi
Publication year - 2021
Publication title -
journal of pharmacy and pharmaceutical sciences
Language(s) - English
Resource type - Journals
ISSN - 1482-1826
DOI - 10.18433/jpps31864
Subject(s) - monoclonal antibody , breast cancer , antibody , medicine , cancer , antigen , monoclonal , immunology , drug , cancer research , cancer cell , pharmacology
Since the first production of monoclonal antibodies about 35 years ago, researchers have found them useful in the treatment and diagnosis of various diseases such as cancer. By developing different types of monoclonal antibodies such as humanized, drug conjugated, or bispecific ones, researchers, have achieved remarkable success in treating several complicated and challenging diseases, targeting specific antigens or receptors makes monoclonal antibodies the right choice to inhibit signaling pathways like programmed death-ligand 1 (PD-L1) or programmed death1 (PD-1) and changing cell behavior. As one of the most common types of malignancies among women, breast cancer is one of the most critical conditions which different types of monoclonal antibodies were designed and produced to treat. Therefore, we reviewed these antibodies in breast cancer, their targets, and their efficacy and toxicity, with more focus on recent PD-L1or PD-1 inhibitor antibodies in breast cancer and beyond.